Effect of triptolide on immune function and tumor cell proliferation in patients cervical cancer
10.3872/j.issn.1007-385x.2020.07.009
- VernacularTitle:雷公藤甲素对宫颈癌患者免疫功能及肿瘤细胞增殖的影响
- Author:
ZHANG Yali
1
;
JIANG Huanhuan
2
;
ZHANG Li
1
;
LIU Xiangjiao
1
;
BI Shengli
1
Author Information
1. a. Department of Obstetrics and Gynecology
2. b. Pharmacy Department, the Second Affiliated Hospital of Hebei North College, Xuanhua 075100, Hebei, China
- Publication Type:Journal Article
- Keywords:
cervical cancer;
triptolide;
immune function;
inflammatory response;
cyclinD1;
estrogen receptor α (ERα)
- From:
Chinese Journal of Cancer Biotherapy
2020;27(7):776-780
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] Objective: To explore the effects of triptolide on immune function and tumor cell proliferation in patients with cervical cancer. Methods: Sixty-two patients with cervical cancer admitted in the Department of Obstetrics and Gynecology of the Second Affiliated Hospital of Hebei North College between July 2015 and April 2018 were randomly divided into the control group (n=31) and the observation group (n=31). All patients received routine treatment after laparoscopy, while those in the observation group received additional triptolide. The treatment efficacy, serum immune cells, inflammatory factors and the levels of cyclinD1, estrogen receptor α (ERα ) were observed and compared between the two groups. Results: The total remission rate of the patients in the observation group was 87.10%, significantly higher than 61.29% in the control group (P<0.05). After treatment, the levels of CD3+ and CD4+ T lymphocytes and CD4+ /CD8+ T lymphocytes in the two groups increased significantly, with more obvious increase in the observation group than that in the control group (P<0.01). The levels of CD8+ and programmed cell death-ligand 1 (PD-L1) T lymphocytes in the two groups decreased significantly after treatment, with a more obvious decrease in observation group than that in control group (P<0.01). After treatment, the levels of interleukin-6 (IL-6), IL-10 and tumor necrosis factor-α (TNF-α) in the two groups decreased, and those in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the positive expression rate of cyclinD1 decreased and the positive expression rate of ER α increased in both groups (all P<0.05), with no significant difference between the two groups (all P>0.05). Conclusion: On the basis of routine surgical treatment, triptolide can effectively improve the immune function, reduce the inflammatory response, inhibit the proliferation of tumor cells and regulate the
expression of cancer-related factors in patients with cervical cancer, which has a certain therapeutic effect on cervical cancer.
- Full text:20200709.pdf
